BeiGene, Ltd., a pioneer in global biotechnology industry, recently shared updates on its Ociperlimab clinical development program and has now become a favorite amongst institutional investors, increaseing their ownership in the company to 45%. The company's stock is marked outperform at a $312 target. As part of their incentive plan, BeiGene has granted 38,919 RSUs to employees. Despite trial discontinuation, the firm's stock is still trading well. The company will announce its 2024 financial results on February 27. Highlights include the appointment of
Giancarlo Benelli as Head of Europe and positive CHMP opinions for TEVIMBRA® as a First-Line Treatment for various cancers.
ImmunityBio has declared its collaboration with BeiGene on a Phase 3 Trial for Non-Small Cell Lung Cancer. However, BeiGene had to discontinue a lung cancer drug study due to limited survival benefit shown in interim data. After these developments, BeiGene's stock leaped by 26%, despite its price and business still lagging the industry. More recently, BeiGene announced its plans to rebrand as 'BeOne Medicines'. Currently, the company has set its sight on establishing a new domicile in Switzerland.
BeiGene, Ltd. News Analytics from Wed, 07 Aug 2024 07:00:00 GMT to Fri, 11 Apr 2025 21:25:27 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
